Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.46 |
| ▸ | CTSD | P07339 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512755 | 0.93 | BACE1 (0.42) | BACE1 | |
| SCHEMBL31596910 | 0.90 | BACE1 (0.47) | BACE1CTSDOPRD1 | |
| SCHEMBL30020949 | 0.90 | BACE1 (0.49) | BACE1CTSDOPRD1 | |
| SCHEMBL30637767 | 0.89 | BACE1 (0.59) | BACE1CTSD | |
| SCHEMBL28964063 | 0.89 | BACE1 (0.59) | BACE1CTSD | |
| SCHEMBL30554853 | 0.89 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL32677403 | 0.88 | BACE1 (0.45) | BACE1CTSD | |
| SCHEMBL31420013 | 0.87 | BACE1 (0.45) | BACE1CTSD | |
| SCHEMBL29853431 | 0.86 | BACE1 (0.41) | BACE1CTSD | |
| SCHEMBL30738394 | 0.86 | BACE1 (0.41) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| CN-116601290-A | Human chimeric antigen receptor neutrophils, compositions, kits and methods of use | 普渡研究基金会 | 2023-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | BACE1 3747/4885CTSD 394/4885OPRD1 3799/4885 |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | BACE1 3747/4885CTSD 394/4885OPRD1 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.